Chinook Therapeutics to Present at Oppenheimer’s 32nd Annual Healthcare Conference
Chinook Therapeutics, Inc. (NASDAQ: KDNY), focused on precision medicines for kidney diseases, will participate in a virtual fireside chat and 1x1 meetings at Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022, at 10:40 am ET. The event will be accessible via a live webcast, with archived recordings available for 90 days on the company’s website. Chinook's lead program is atrasentan, targeting IgA nephropathy, alongside other promising drug candidates for severe chronic kidney disorders.
- None.
- None.
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat and 1x1 meetings at Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 10:40 am ET.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
What is the date and time of Chinook Therapeutics' presentation at the Oppenheimer Healthcare Conference?
Where can I access the live webcast for Chinook Therapeutics' event?
What is Chinook Therapeutics' lead program?
How long will the archived recordings of the presentation be available?
Which other drug candidates is Chinook Therapeutics developing?
